Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AN2 Therapeutics, Inc. ANTX
$5.02
-$0.04 (-0.79%)
На 18:05, 12 мая 2023
+378.09%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
99923905.00000000
-
week52high
23.58
-
week52low
5.05
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-2.27000000
-
Last Dividend
7.13854200
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | 19 апр 2022 г. | |
| Evercore ISI Group | Outperform | 19 апр 2022 г. | |
| Cowen & Co. | Outperform | 19 апр 2022 г. | |
| SVB Leerink | Outperform | Outperform | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Easom Eric | D | 4907 | 23 | 14 ноя 2022 г. |
| Easom Eric | D | 4930 | 4413 | 10 ноя 2022 г. |
| Easom Eric | D | 4907 | 10111 | 09 ноя 2022 г. |
| Easom Eric | D | 15018 | 1255 | 08 ноя 2022 г. |
| Easom Eric | D | 16273 | 5800 | 08 ноя 2022 г. |
| Easom Eric | D | 6943 | 10167 | 07 ноя 2022 г. |
| Easom Eric | D | 4907 | 2036 | 07 ноя 2022 г. |
| Easom Eric | D | 17110 | 8828 | 04 ноя 2022 г. |
| Easom Eric | D | 25938 | 3083 | 03 ноя 2022 г. |
| Easom Eric | D | 29021 | 11082 | 03 ноя 2022 г. |
Новостная лента
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
GlobeNewsWire
19 окт 2022 г. в 08:00
MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from October 19-24, 2022 in Washington D.C. highlighting new data for epetraborole. AN2 Therapeutics is currently enrolling patients in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of nontuberculous mycobacterial (NTM) lung disease.
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
29 авг 2022 г. в 07:00
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, President and CEO will present at the H.C. Wainwright 24th Annual Global Investment Conference
U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week
Seeking Alpha
26 мар 2022 г. в 02:55
U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15
Benzinga
25 мар 2022 г. в 15:23
AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million. The Company announced IPO plans earlier this month.
AN2 Therapeutics Stock to List Today
Barrons
25 мар 2022 г. в 09:39
Biotech AN2 Therapeutics sold 4.6 million shares at $15 each, the mid-point of its $14 to $16 range. It's the second conventional IPO this month.